A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2018
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 07 Jun 2018 Status changed from active, no longer recruiting to discontinued.
- 01 Feb 2018 Planned End Date changed from 16 Jan 2018 to 9 Jul 2018.
- 09 Oct 2017 Planned End Date changed from 21 Sep 2017 to 16 Jan 2018.